FindTrial
Sign In

Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02014428
Enrollment
Unknown
Registered
2013-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2013-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Vaginitis

Brief summary

To evaluate the effectiveness of low molecular weight hyaluronic acid oral tablets for the treatment of atrophic vaginitis.

Interventions

DIETARY_SUPPLEMENTHyaluronic acid
DRUGPlacebo

Sponsors

AGUNCO Obstetrics and Gynecology Centre
Lead SponsorOTHER

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years

Inclusion criteria

* at least 12 months postmenopausal * mucosal atrophy and the main bothersome related symptoms, such as itching, burning, and dyspareunia.

Design outcomes

Primary

MeasureTime frameDescription
Atrophic vaginal changesChange from baseline epithelium at 3 monthsMorphometric analysis of biopsies.

Secondary

MeasureTime frameDescription
Assessment of ItchingChange from baseline Itching at 3 monthsScale: absent, mild, moderate, severe.
Assessment of BurningChange from baseline Burning at 3 monthsScale: absent, mild, moderate, severe.
Assessment of DyspareuniaChange from baseline Dyspareunia at 3 monthsScale: absent, mild, moderate, severe.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026